Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 3:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Prevention & Control Clear all
Completed Phase 2 Interventional Results available

Urinary Track Infection Prevention After Urogynecological Surgery

NCT03818321
View directory record Official record
Conditions
Urinary Tract Infections, Urinary Retention Postoperative, Pelvic Organ Prolapse
Interventions
Methenamine Hippurate 1 g tablet, Placebo tablet
Drug
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 13, 2022 · Synced Sep 9, 2026, 3:17 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

The University of Oregon ACCESS Project

NCT07264621
View directory record Official record
Conditions
School Attendance, School Climate, School Engagement, School Exclusion, Externalizing Behavior, Disparities, Teacher-student Relationships, Stress, Emotional Regulation, Depression
Interventions
Inclusive Skill-building Learning Approach (ISLA), Family Check-Up Online (FCU-O), FCU-Online with telehealth coaching
Behavioral
Lead sponsor
University of Oregon
Other
Eligibility
11 Years and older
Enrollment
1,440 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
13
States / cities
Cottage Grove, Oregon • Eugene, Oregon • Springfield, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Sep 9, 2026, 3:17 AM EDT
Completed Phase 3 Interventional

Study of Neurologic Progression With Motexafin Gadolinium and Radiation Therapy (SMART)

NCT00054795
View directory record Official record
Conditions
Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Metastases, Neoplasm
Interventions
Motexafin Gadolinium
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
44
States / cities
Phoenix, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated May 7, 2007 · Synced Sep 9, 2026, 3:17 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

NCT02565511
View directory record Official record
Conditions
Alzheimers Disease
Interventions
CAD106 Immunotherapy, Placebo to CAD106, CNP520, Placebo to CNP520, Alum
Biological · Other · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
60 Years to 75 Years
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
78
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2021 · Synced Sep 9, 2026, 3:17 AM EDT
Completed Phase 3 Interventional Results available

Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE I)

NCT00249795
View directory record Official record
Conditions
Atrial Fibrillation, Cardiovascular Disease
Interventions
Irbesartan, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
9,016 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 14, 2010 · Synced Sep 9, 2026, 3:17 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant

NCT04693637
View directory record Official record
Conditions
Adenovirus Infection, BK Virus Infection, Cytomegalovirus Infections, Epstein-Barr Virus Infections, Human Herpes Virus-6 Infection, JC Virus Infection
Interventions
Posoleucel (ALVR105)
Biological
Lead sponsor
AlloVir
Industry
Eligibility
1 Year and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
16
States / cities
Birmingham, Alabama • Duarte, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Sep 9, 2026, 3:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluating a Preference-based Intervention for Increasing Colorectal Cancer Screening

NCT00810771
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Standard Information, Preference-tailored Information
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
50 Years to 78 Years
Enrollment
466 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
2
States / cities
Ann Arbor, Michigan • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 1, 2015 · Synced Sep 9, 2026, 3:17 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Safety and Efficacy of T89 in the Prevention and Treatment of Adults With Acute Mountain Sickness (AMS)

NCT04993729
View directory record Official record
Conditions
Acute Mountain Sickness (AMS)
Interventions
T89 capsule, Placebo capsule
Drug
Lead sponsor
Tasly Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
853 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Sep 9, 2026, 3:17 AM EDT
Recruiting Not applicable Interventional

Retinal Detachment Prevention (Laser Prophylaxis) in Stickler Syndrome (SS)

NCT07146516
View directory record Official record
Conditions
Stickler Syndrome Type 1, Stickler Syndrome Type 2
Interventions
Prophylactic (non-invasive) Laser Retinopexy
Procedure
Lead sponsor
Helen Keller Eye Research Foundation
Other
Eligibility
Not listed
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
5
States / cities
Birmingham, Alabama • Royal Oak, Michigan • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 9, 2026, 3:17 AM EDT
Completed Not applicable Interventional

A Randomized Controlled Trial of a Multicomponent Walking Aid Program for People With MS

NCT04145934
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
ADSTEP
Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Sep 9, 2026, 3:17 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis

NCT00808132
View directory record Official record
Conditions
Menopause, Osteoporosis
Interventions
bazedoxifene 20 mg/ conjugated estrogens 0.45 mg, bazedoxifene 20 mg/ conjugated estrogens 0.625 mg, bazedoxifene 20 mg, conjugated estrogens 0.45 mg/ medroxyprogesterone acetate 1.5 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 64 Years · Female only
Enrollment
1,886 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
143
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 119 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2014 · Synced Sep 9, 2026, 3:17 AM EDT
Completed Phase 3 Interventional Results available

Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation

NCT00412984
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
warfarin, apixaban
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
Not listed
Enrollment
20,976 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
284
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 206 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Sep 9, 2026, 3:17 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Pagibaximab Injection in Very Low Birth Weight Neonates for Prevention of Staphylococcal Sepsis

NCT00646399
View directory record Official record
Conditions
Staphylococcal Sepsis
Interventions
Placebo, Pagibaximab 50 mg/mL
Drug
Lead sponsor
Biosynexus Incorporated
Industry
Eligibility
Up to 48 Hours
Enrollment
1,579 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Gaithersburg, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 23, 2011 · Synced Sep 9, 2026, 3:17 AM EDT
Completed Not applicable Interventional

Primary Care-Based Interventions to Reduce Alcohol Use Among HIV Patients

NCT01671501
View directory record Official record
Conditions
HIV, Acquired Immunodeficiency Syndrome, Alcoholism, Alcoholic Intoxication, Substance-Related Disorders
Interventions
Motivational Interviewing, Email Feedback, Usual Care
Behavioral · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 100 Years
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 9, 2018 · Synced Sep 9, 2026, 3:17 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis

NCT04365868
View directory record Official record
Conditions
Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis, Cirrhosis
Interventions
belapectin, Placebo
Drug
Lead sponsor
Galectin Therapeutics Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
81
States / cities
Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 9, 2026, 3:17 AM EDT
Completed Phase 3 Interventional Results available

Comparing Safety and Immunogenicity of HEPLISAV-B® to Engerix-B® in Chronic Kidney Disease (CKD) Patients

NCT00985426
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
HEPLISAV-B, Engerix-B, Placebo
Biological · Other
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
521 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Sep 9, 2026, 3:17 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Dissemination of an Adolescent Obesity Prevention Intervention to Louisiana Schools

NCT06335056
View directory record Official record
Conditions
Treatment (ProudMe), Waitlist Control
Interventions
ProudMe, Waitlist Control
Behavioral
Lead sponsor
Louisiana State University and A&M College
Other
Eligibility
10 Years to 15 Years
Enrollment
480 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 27, 2024 · Synced Sep 9, 2026, 3:17 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of ChimeriVax-WN02 West Nile Vaccine in Healthy Adults

NCT00442169
View directory record Official record
Conditions
West Nile Fever
Interventions
ChimeriVax-WN02 Low Dose, ChimeriVax-WN02 Medium Dose, ChimeriVax-WN02 High Dose, 0.9% Saline solution, 0.9 % NaCl solution
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
5
States / cities
Phoenix, Arizona • Idaho Falls, Idaho • Lenexa, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Sep 9, 2026, 3:17 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine

NCT03432286
View directory record Official record
Conditions
Episodic Migraine
Interventions
Galcanezumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Years to 17 Years
Enrollment
533 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
38
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Sep 9, 2026, 3:17 AM EDT
Completed Phase 2 Interventional

Study Of Prevention of Chemo-Induced Nausea and Vomiting Caused By Moderately Emetogenic Chemotherapy

NCT00104403
View directory record Official record
Conditions
Nausea and Vomiting, Chemotherapy-Induced, Chemotherapy-Induced Nausea and Vomiting
Interventions
GW679769, Dexamethasone, Ondansetron Hydrochloride
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
722 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
47
States / cities
Birmingham, Alabama • Corona, California • Greenbrae, California + 43 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Sep 9, 2026, 3:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Acceptability Study of the UC-781 Microbicide Gel Applied Rectally

NCT00408538
View directory record Official record
Conditions
HIV Infections
Interventions
UC-781 microbicide gel (0.1% and 0.25%), placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 3, 2009 · Synced Sep 9, 2026, 3:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Impact of Patient Involvement in Decision-Making About Heart Disease Prevention

NCT00315978
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Heart-to-Heart Decision Aid
Device
Lead sponsor
University of North Carolina
Other
Eligibility
35 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2004
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 9, 2007 · Synced Sep 9, 2026, 3:17 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Randomized Control Trial of Family-Based HIV Prevention for Latinos

NCT01635335
View directory record Official record
Conditions
HIV, Sexually Transmitted Infections
Interventions
Latino STYLE
Behavioral
Lead sponsor
University of South Florida
Other
Eligibility
14 Years and older
Enrollment
542 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2016
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 20, 2016 · Synced Sep 9, 2026, 3:17 AM EDT
Completed Phase 3 Interventional Results available

Cardiovascular Inflammation Reduction Trial

NCT01594333
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Methotrexate, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
4,786 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
404
States / cities
Birmingham, Alabama • Fort Payne, Alabama • Guntersville, Alabama + 296 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2020 · Synced Sep 9, 2026, 3:17 AM EDT